This EZH2 inhibitor has the highest efficacy in EZH2-mutated DLBCL patients belonging to the GCB subtype [46], and the mutation found in Su-Dhl-4 cells has been reported as a potential biomarker for response to EZH2 inhibitors [47]. This evidence concerns the gene EZH2 and diffuse large B-cell lymphoma.